Q1 2022 13F Holders as of 3/31/2022
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
79.4M
-
Number of holders
-
98
-
Total 13F shares, excl. options
-
35.1M
-
Shares change
-
-131K
-
Total reported value, excl. options
-
$499M
-
Value change
-
-$2.94M
-
Number of buys
-
43
-
Number of sells
-
-33
-
Price
-
$14.19
Significant Holders of Akero Therapeutics, Inc. - COMMON STOCK (AKRO) as of Q1 2022
108 filings reported holding AKRO - Akero Therapeutics, Inc. - COMMON STOCK as of Q1 2022.
Akero Therapeutics, Inc. - COMMON STOCK (AKRO) has 98 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 35.1M shares
of 79.4M outstanding shares and own 44.27% of the company stock.
Largest 10 shareholders include Skorpios Trust (4.91M shares), JANUS HENDERSON GROUP PLC (3.37M shares), ALKEON CAPITAL MANAGEMENT LLC (2.42M shares), WELLINGTON MANAGEMENT GROUP LLP (2.23M shares), Atlas Venture Life Science Advisors, LLC (2.23M shares), venBio Partners LLC (2.17M shares), BlackRock Inc. (1.9M shares), Point72 Asset Management, L.P. (1.85M shares), Redmile Group, LLC (1.6M shares), and Yiheng Capital Management, L.P. (1.55M shares).
This table shows the top 98 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.